VBIO Valion Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1787740 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-49.6%
TTM net income YoY-16.9%
TTM EPS YoY—
Revenue 3-yr CAGR-35.8%
Net income 3-yr CAGR—
Margins
Gross margin-58.1%
Operating margin-1,210.8%
Net margin-1,557.3%
FCF margin-1,263.5%
EBITDA margin-1,210.4%
Returns
ROE-240.3%
ROA-156.0%
ROIC (approx.)-1,514.1%
Asset turnover0.10x
Leverage & solvency
Liabilities / assets10.2%
Debt / equity0.00x
Current ratio5.86x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-29.7%
Payout ratio—
Capex / revenue2.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2026-03-302026-03-30 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | $146,000 | $86,000 | $70,000 | $180,000 |
| Cost of revenue | — | — | — | — | $291,000 | $32,000 | $20,000 | $419,000 |
| Gross profit | — | — | — | — | -$145,000 | $54,000 | $50,000 | -$239,000 |
| R&D expense | $2.70M | $1.85M | $1.85M | $1.28M | $858,000 | $655,000 | $335,000 | $333,000 |
| SG&A expense | $3.72M | $3.78M | $3.78M | $1.75M | $1.06M | $1.02M | $1.04M | $730,000 |
| Operating income | -$6.42M | -$5.63M | — | -$1.98M | -$2.48M | -$1.68M | -$1.38M | -$298,000 |
| Interest expense | $691,000 | $648,000 | $648,000 | — | — | $0 | $0 | — |
| Net income | -$7.10M | -$6.20M | — | -$2.85M | -$2.60M | -$1.93M | -$1.50M | -$1.48M |
| EBITDA | -$6.07M | -$5.63M | — | -$1.97M | -$2.48M | -$1.68M | -$1.38M | -$298,000 |
| EPS (basic) | -2.17 | -2.23 | — | — | -1.97 | -2.19 | -2.52 | — |
| EPS (diluted) | — | — | — | — | — | -2.19 | -2.52 | — |
| Weighted avg. shares (diluted) | — | — | — | — | — | 881,294 | 596,368 | — |
| Banking | ||||||||
| Net interest income | — | — | — | — | — | $3,000 | $4,000 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.11M | $7.21M | — | $12.64M | $3.45M | $1.18M | $669,000 | $2.00M |
| Receivables | — | — | — | — | $19,000 | $13,000 | $13,000 | $69,000 |
| Inventory | $750,000 | $750,000 | — | $0 | $4,000 | $283,000 | $306,000 | $319,000 |
| Current assets | $3.38M | $8.65M | — | $13.01M | $3.74M | $1.84M | $1.26M | $2.64M |
| PP&E, net | $12.34M | $12.64M | — | $12.64M | $12,000 | $120,000 | $118,000 | $2,000 |
| Goodwill | $3.46M | $3.46M | — | $3.46M | — | — | — | $0 |
| Intangibles | $2.24M | $2.24M | — | $2.24M | $2.24M | — | — | $0 |
| Total assets | $32.47M | $38.22M | — | $31.61M | $6.23M | $4.51M | $3.78M | $2.81M |
| Current liabilities | $3.05M | $2.62M | — | $646,000 | $638,000 | $821,000 | $741,000 | $272,000 |
| Total liabilities | $20.59M | $19.67M | — | $7.44M | $638,000 | $821,000 | $741,000 | $272,000 |
| Shareholders' equity | $4.25M | $11.06M | — | $16.80M | $3.41M | $3.69M | $3.04M | $2.54M |
| Shares outstanding | 4.15M | 2.88M | — | 2.53M | 1.66M | 965,899 | 705,641 | 556,902 |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.28M | -$5.01M | — | -$2.29M | -$2.00M | -$1.83M | -$889,000 | -$1.36M |
| Capital expenditure | $57,000 | $7,000 | — | $25,000 | $10,000 | $3,000 | $0 | $0 |
| Free cash flow | -$5.34M | -$5.02M | — | -$2.31M | -$2.01M | -$1.83M | -$889,000 | -$1.36M |
| Investing cash flow | -$57,000 | -$7,000 | — | -$149,000 | -$10,000 | -$20,000 | -$526,000 | $0 |
| Financing cash flow | $231,000 | -$44,000 | — | $11.63M | $4.27M | $2.36M | $82,000 | $1.18M |
| Depreciation & amortization | $358,000 | $4,000 | — | $3,000 | $0 | $1,000 | $1,000 | $0 |
| Stock-based compensation | $133,000 | $208,000 | — | $149,000 | $138,000 | $177,000 | $100,000 | $63,000 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.